Identity
- Security key
- 21424
- Ticker
- SCYX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2014-05-02
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- SCYX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $47,857,619.29
- Shares outstanding (class)
- 9,930,329
- Shares outstanding (weighted)
- 9,949,609
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 29
- Location
- JERSEY CITY, NJ
- Homepage
- https://www.scynexis.com
- Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Market cap and share counts drift.